Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

Infect Immun. 2005 Jun;73(6):3814-6. doi: 10.1128/IAI.73.6.3814-3816.2005.

Abstract

Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induced unprecedented 100% protection of guinea pigs from high-dose aerosol challenge with Mycobacterium tuberculosis, suggesting a strategy for enhancing and prolonging the efficacy of BCG.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Bacterial / genetics*
  • Antigens, Bacterial / immunology
  • BCG Vaccine / immunology*
  • Guinea Pigs
  • Poxviridae / genetics*
  • Tuberculosis / prevention & control*
  • Vaccines, Synthetic / immunology*

Substances

  • Antigens, Bacterial
  • BCG Vaccine
  • Vaccines, Synthetic
  • antigen 85, Mycobacterium bovis